Company Announcement – #6 / 2022
Zealand Pharma is hosting a conference call on March 10 at 4:00 p.m. CET (10:00 a.m. ET) to present the full annual results of 2021
Copenhagen, DK and Boston, MA, USA March 3, 2022 — Zeeland Pharma A/S (Nasdaq: ZEAL) (CVR-No. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based drugs, announced that it will host a conference call on March 10, 2022 at 4:00 p.m. pm CET (10 am ET) following the announcement of results for the full year 2021.
President and CEO Emmanuel Dulac, President of Zealand Pharma US Frank Sanders, Senior Vice President and Chief Financial Officer Matt Dallas and Executive Vice President and Chief Medical Officer Adam Steensberg will present on the call. The presentation will be followed by a question and answer session. The conference call will be in English and the call-in numbers are:
|Denmark, Copenhagen………..||+45 32 720 417|
|Denmark, toll-free …………………………||+80 711 246|
|France paris…………………………..||+33 (0) 170 700 781|
|Netherlands, Amsterdam……..||+31 (0) 207956614|
|UK…………………….||+44 (0) 844 481 9752|
|United States……………………………||+1 646 741 3167|
|International…………………………..||+44 (0) 2071 928338|
|Confirmation code: …………….||9554999|
A live audio webcast of the call, including a slide presentation, will be available via the following link, https://edge.media-server.com/mmc/p/34a8yoe2and will be accessible in the Investors section of the Zealand website (www.zealandpharma.com/investor). Due to increased demand for conference call services, it may take longer to connect to the call. Participants are advised to register for the webcast 30 minutes before the scheduled start, if possible. A recording of the event and a transcript will be available on the Investors section of Zealand’s website after the call.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, development and commercialization of peptide-based drugs. More than 10 drug candidates invented by Zealand have reached the stage of clinical development, of which two have reached the market and three candidates are in late-stage development. Additionally, in-licensing collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from the experimental Zeeland-invented peptide agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has a presence across the United States, including Boston and Marlborough (MA). For more information on Zealand’s business and activities, please visit http://www.zealandpharma.com.
This announcement may contain forward-looking statements, including “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on beliefs and assumptions and on information currently available to the management of Zealand, including with respect to the company’s anticipated 2021 revenues and expenses and potential FDA approval of the product. All statements other than statements of historical facts contained in this announcement are forward-looking statements, including statements regarding the expected final terms of the investment. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, ” estimates”, “predicts”, “potential” or “continue” or the negative form of these terms or any other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievements of Zealand to be materially different from any future results, performance or achievements expressed or implied by the statements. prospective. These risks and uncertainties include, but are not limited to, the risks and uncertainties set out in the “Risk Factors” section of Zealand’s Annual Report on Form 20-F for the financial year ended 31 December 2019 filed with the SEC on March 13. , 2020 and subsequent reports that Zealand has filed or will file with the SEC. Forward-looking statements represent Zealand’s beliefs and assumptions only as of the date of this announcement. Although Zealand believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, Zealand undertakes no obligation to publicly update–forward-looking statements for any reason after the date of this announcement in order to conform any of the forward-looking statements to actual results or to changes in its expectations.
For more information, please contact: